心力衰竭的分子机制和干预方法 (综述)
Shuang Guo1, Yingqing Hu2, Li Ling2
1Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China.
International journal of molecular medicine
|June 13, 2025
概括
心力衰竭是一种复杂的疾病,由各种心血管疾病引起. 这篇评论探讨了它的分子机制,提供了对预防和治疗策略的见解.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 病理生理学 病理生理学
背景情况:
- 心力衰竭是一个严重的健康问题,通常代表心律不整和心肌梗塞等疾病的末期阶段.
- 心血管疾病通过包括心肌纤维化,细胞死亡和线粒体功能受损在内的机制导致心力衰竭.
- 心力衰竭的复杂分子路径尚未完全理解,这限制了有效的干预措施.
研究的目的:
- 审查了解心力衰竭的最新进展.
- 阐明心力衰竭背后的复杂分子机制.
- 为预防和治疗心力衰竭提供基于证据的策略.
主要方法:
- 对最近关于心力衰竭的研究进行了全面的文献综述.
- 分析导致心力衰竭的病理机制.
- 综合有关心力衰竭所涉及的分子通路的当前知识.
主要成果:
- 确定了关键的病理机制:心肌纤维化,高,细胞死亡,线粒体功能障碍,血管重塑和失调.
- 强调了详细的分子机制的复杂性和难以捉摸性.
- 编制了对当前研究进展的回顾.
结论:
- 了解心力衰竭的分子基础对于开发有效治疗方法至关重要.
- 需要对这些复杂机制进行进一步的研究.
- 本综述为未来心力衰竭的预防和干预策略提供了基础.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics
350
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
Heart Failure Drugs: Inotropic Agents
543
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
Pathophysiology of Cardiac Performance
611
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
611


